ORCID

0009-0003-2696-2259 (Maniattu), 0009-0009-7763-614X (Maliakal)

Document Type

Article

Publication Date

2026

DOI

10.1210/jcemcr/luag251

Publication Title

JCEM Case Reports

Volume

4

Issue

12

Pages

luag251 (6 pp.)

Abstract

Denosumab, a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor, is widely used to treat osteoporosis. Its role as a trigger for autoimmune hepatitis (AIH) remains uncertain. We report a 68-year-old woman with osteoporosis and Hashimoto thyroiditis who developed jaundice and severe hepatocellular liver injury after 3 years of denosumab therapy. Alternative viral, obstructive, and metabolic causes were excluded. Liver biopsy demonstrated interface hepatitis with a lymphoplasmacytic portal infiltrate consistent with AIH, and autoimmune serologies were positive. Hemophagocytic lymphohistiocytosis was excluded, and an International AIH Score of 17 supported a diagnosis of definite AIH. Treatment with corticosteroid-based immunosuppression resulted in complete biochemical remission, and denosumab was discontinued with transition to zoledronic acid to prevent rebound bone loss. Whether this case represents drug-induced autoimmune-like hepatitis or de novo idiopathic AIH occurring in a susceptible individual cannot be determined definitively. Clinicians should maintain a low threshold for evaluating liver injury in patients receiving denosumab who develop jaundice or marked transaminase elevation.

Rights

© The Authors 2026.

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) License, which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Data Availability

Article states: "Original data generated and analyzed during this study are included in this published article."

Original Publication Citation

Maniattu, J., Antony, M., & Maliakal, A. (2026). Autoimmune hepatitis following long-term denosumab therapy in a patient with Hashimoto thyroiditis. JCEM Case Reports, 4(12), Article luag251. https://doi.org/10.1210/jcemcr/luag251

Share

COinS